ProVise Management Group LLC Purchases 18,724 Shares of Pfizer Inc. $PFE

ProVise Management Group LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 16.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,881 shares of the biopharmaceutical company’s stock after acquiring an additional 18,724 shares during the period. ProVise Management Group LLC’s holdings in Pfizer were worth $3,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. increased its position in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi lifted its holdings in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new position in Pfizer in the first quarter worth approximately $389,861,000. Goldman Sachs Group Inc. grew its position in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 2.8%

Shares of NYSE:PFE opened at $25.08 on Friday. The business’s 50 day moving average price is $24.80 and its 200-day moving average price is $24.44. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a market capitalization of $142.57 billion, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 100.00%.

Analyst Ratings Changes

Several research firms have recently commented on PFE. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.